BIOTECH MARKET RESEARCH $NKTR | Ep. 614

Nektar Therapeutics

Nektar (NKTR) is approaching a critical inflection point with the upcoming Phase 2b data readout for REZPEG in moderate-to-severe atopic dermatitis. Investors are closely watching whether its IL-2Rα agonism approach can deliver meaningful disease modification, a key differentiator from existing therapies. Given the high market anticipation and potential volatility, the stock could see significant swings—potentially ±150%—depending on the strength of the efficacy and safety data.

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.

ALERT: REZPEG Phase 2b Study in Moderate-to-Severe Atopic Dermatitis

DATE: Q2 2025

IMPLIED VOLATILITY: +/- 150%

BACKGROUND: